Diagnosis: What’s holding back UK life sciences?

The country aims to become the world’s third-largest life sciences economy by 2035, but stalled investments, regulatory hurdles, and talent shortages are raising questions about whether the target is achievable, finds Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

New IP guidance promises to transform the NHS. Will it deliver?

2 December 2025 The move could unlock billions in life sciences collaborations and position the UK to rival the US and China. But turning a famously conservative, patient-safety-first institution into a commercially savvy innovation hub will be no small feat.

Europe

What people talked about at London Life Sciences Week

21 November 2025 The week exposed fractures in the UK's industry—but also unexpected reasons for optimism. Five themes dominated conversations about the direction of the country's life sciences sector.

Europe

NHS updates outdated IP rules in bid to revive UK life sciences

20 November 2025 The country’s public health service has replaced its IP framework with a nine-step plan, as the government tries to reposition the UK as a global life sciences leader.

More features

Winston & Strawn and Taylor Wessing UK plan transatlantic combo

Teva scrubs 200-plus Orange Book patents after FTC turns the screw

Arnold & Porter grows life sciences transactions bench with London hire

Novo Nordisk ramps up semaglutide defence as generics lurk

Cooley drafts in 30-strong life sciences team from rival

US govt backs Hikma over ‘skinny label’ rules

Marks & Clerk adds multi-jurisdictional disputes expert

USPTO issues guidance to support patent eligibility declarations

Diagnosis: What’s holding back UK life sciences?

More on this story

Editor's picks

Editor's picks

More features